Eli Lilly's gene therapy shows promise in reducing cholesterol levels, while the company secures new vaccine developers to expand its infectious disease portfolio.
Eli Lilly has made significant strides with its gene-editing therapy, reporting that a high dose reduced cholesterol levels by 62% in participants of a Phase 1 clinical trial. This early test is encouraging for those seeking a one-time treatment to lower their LDL or "bad" cholesterol. The company acquired this therapy as part of its $1 billion buyout of Verve Therapeutics last year, and the study did not report any serious adverse events, marking an improvement from previous safety concerns.
In another development, Eli Lilly has agreed to purchase three early- and mid-stage vaccine developers: Curevo, LimmaTech Biologics, and Vaccine Company. These acquisitions could cost up to nearly $4 billion and will significantly expand the company's presence in infectious diseases. With a robust cash flow from its booming GLP-1 business, Lilly is diversifying into areas such as cancer, autoimmune diseases, and sleep disorders.
These moves align with Lilly's broader strategy of preventing serious health problems through preventive care. The addition of these vaccine developers underscores the company’s commitment to addressing a wider range of health issues, particularly in infectious diseases that have not been a priority for them until now.
Stay tuned for more updates as we continue to follow Eli Lilly's strategic initiatives and their potential impacts on the pharmaceutical landscape.
